Tag:
Apotex
Latest Headlines
Latest Headlines
Apotex sued over problems on contraceptive packaging line
Forty-five women are seeking $800 million (U.S. $778.8 million) in a class-action lawsuit filed Friday, claiming a packaging foul-up by Apotex led them to take placebos instead of the active birth control pills.
More recalls as Hospira struggles to right manufacturing
It has been a particularly bad few days for Hospira, with both the company and the FDA alerting healthcare providers of problems with multiple lots of its drugs. That was in addition to an alert for one of its medical products.
Drugmakers 'illegally' withhold samples from would-be copycats
Risk-management plans may be a burden for new drug launches, but they're proving to be a weapon against generic competition, too. As the New York Times reports, generics makers can't buy the supplies they need to knock off a product, thanks to REMS restrictions. So, they have to resort to asking branded drugmakers for supplies--and some of those companies aren't cooperating.
FDA on Apotex's case for plant problems
The generic drug manufacturer, which for nearly two years had its products banned from the U.S., has received a warning letter for two of its in Canada plants, one in Ontario and one in Toronto that has received a warning letter before.
Merck loses a patent ruling on blockbuster Nasonex
Even as the clock is ticking down on the patent for its super blockbuster Singulair, Merck ($MRK) got smacked Friday with a negative decision in its battle with genericmaker Apotex over Merck's blockbuster Nasonex spray.
Generic floodgates open for Plavix in U.S.
Plavix is a blood thinner from Bristol-Myers Squibb ($BMY). Generic Plavix is a Bristol-Myers profits thinner that is going to be produced by just about everybody and their brother.
UPDATED: Supreme Court upholds Unigene's nasal delivery patent
Unigene Laboratories can hold on to its patent for Fortical, after the Supreme Court denied Apotex's petition this week.
UPDATED: Apotex recalls BP med over empty capsules
Bad news coming out of Canada for Apotex. Canadian regulators are informing hypertensive patients the drugmaker is conducting a voluntary recall of one lot of Apo-Ramipril 5-mg capsules.
Apotex says FDA import ban, delays 'decimated' its business
Apotex claims in a filing that the FDA "decimated" its business by issuing an import ban against drugs made at two of its Canadian facilities.
Sanofi, BMS collect their $444M in Plavix damages
Apotex has finally paid its Plavix dues. The generics maker has handed over $444 million to Sanofi ( $SNY ) and Bristol-Myers Squibb ( $BMY ), as repayment for its premature launch of generic Plavix back...
